EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Efficacy of CDK4/6 Inhibitor Plus Aromatase Inhibitor versus Fulvestrant in Chinese Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer

Yujing Tan, Cheng Zeng iD, Jiuda Zhao, Weihong Zhao, Hanfang Jiang, Jiani Wang, Fei Ma

Breast Cancer: Targets and Therapy · 2026-06 · Volume 18 · 1-11

DOI: 10.2147/bctt.s574628 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer: Targets and Therapy, 2026-06. Verfasst von Yujing Tan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Scien…. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

AICDK4/6 inhibitorHR+/HER2- breast canceradvanced breast cancerfulvestrant

Autor:innen und Institutionen

  • Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of Chin…
  • Department of Medical Oncology, Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University, Qinghai, People's Republic of China.
  • Department of Medical Oncology, Chinese PLA General Hospital, Beijing, People's Republic of China.
  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, People's Republic of China.

ORCID-Profile: Cheng Zeng

Zitieren

APA

Tan, Y., Zeng, C., Zhao, J., Zhao, W., Jiang, H., Wang, J., & Ma, F. (2026). Efficacy of CDK4/6 Inhibitor Plus Aromatase Inhibitor versus Fulvestrant in Chinese Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer. Breast Cancer: Targets and Therapy, Volume 18, 1-11. https://doi.org/10.2147/bctt.s574628

Vancouver

Tan Y, Zeng C, Zhao J, Zhao W, Jiang H, Wang J, et al. Efficacy of CDK4/6 Inhibitor Plus Aromatase Inhibitor versus Fulvestrant in Chinese Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer. Breast Cancer: Targets and Therapy. 2026;Volume 18:1-11. doi:10.2147/bctt.s574628

BibTeX
@article{Tan2026,
  author = {Tan, Yujing and Zeng, Cheng and Zhao, Jiuda and Zhao, Weihong and Jiang, Hanfang and Wang, Jiani and Ma, Fei},
  title = {Efficacy of CDK4/6 Inhibitor Plus Aromatase Inhibitor versus Fulvestrant in Chinese Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer},
  journal = {Breast Cancer: Targets and Therapy},
  year = {2026},
  volume = {Volume 18},
  pages = {1--11},
  doi = {10.2147/bctt.s574628}
}
Kostenlos starten →